中华行为医学与脑科学杂志
中華行為醫學與腦科學雜誌
중화행위의학여뇌과학잡지
CHINESE JOURNAL OF BEHAVIORAL MEDICINE AND BRAIN SCIENCE
2012年
6期
484-487
,共4页
5-HT再摄取抑制剂%性功能障碍%催乳素
5-HT再攝取抑製劑%性功能障礙%催乳素
5-HT재섭취억제제%성공능장애%최유소
Selective serotonin reuptake inhibitor%Sexual dysfunction%Prolactin
目的 探讨丁螺环酮对使用5-HT再摄取抑制剂(SSRI)维持治疗的缓解期女性抑郁症患者性功能以及血清催乳素水平的影响.方法 筛选120例以单一SSRI类抗抑郁剂治疗至少6月、具有固定配偶、汉密尔顿抑郁量表17项版本(HMAD-17)评分小于7分的康复期抑郁症女性患者,以亚利桑那性经验量表(ASEX)判定性功能障碍(SD)者40例,并予丁螺环酮15～30 mg/d治疗4周,匹配社会人口学相符的正常对照组、非SD患者组(NSD)各40例,比较对照组、NSD组和丁螺环酮治疗前后SD组性功能和血浆催乳索水平,并分析SD可能的临床相关因素.结果 120例康复期抑郁症患者SD总体发生率为33.3％,丁螺环酮治疗后性功能好转率为60％.SD组合并丁螺环酮治疗后ASEX总分、5个分因子分值低于合并用药前,差异有显著性(均P＜0.01)；SD组合并丁螺环酮治疗后血清催乳素水平[(20.38±11.91)ng/ml]高于正常对照组[(14.2±12.15)ng/ml],差异有显著性(P=0.008),但与SD组合并用药前[(18.15±9.84) ng/ml]相比差异无统计学意义(P=1.0).合并丁螺环酮治疗前患者ASEX总分与氟西汀(r=0.504,P=0.002)和帕罗西汀(r=0.377,P=0.013)剂量显著相关.在正常组、NSD组以及SD组合并丁螺环酮治疗前后均未发现ASEX总分与血催乳素水平显著相关.结论 丁螺环酮辅助治疗可能有助于缓解SSRI类抗抑郁剂所致的性功能障碍.
目的 探討丁螺環酮對使用5-HT再攝取抑製劑(SSRI)維持治療的緩解期女性抑鬱癥患者性功能以及血清催乳素水平的影響.方法 篩選120例以單一SSRI類抗抑鬱劑治療至少6月、具有固定配偶、漢密爾頓抑鬱量錶17項版本(HMAD-17)評分小于7分的康複期抑鬱癥女性患者,以亞利桑那性經驗量錶(ASEX)判定性功能障礙(SD)者40例,併予丁螺環酮15～30 mg/d治療4週,匹配社會人口學相符的正常對照組、非SD患者組(NSD)各40例,比較對照組、NSD組和丁螺環酮治療前後SD組性功能和血漿催乳索水平,併分析SD可能的臨床相關因素.結果 120例康複期抑鬱癥患者SD總體髮生率為33.3％,丁螺環酮治療後性功能好轉率為60％.SD組閤併丁螺環酮治療後ASEX總分、5箇分因子分值低于閤併用藥前,差異有顯著性(均P＜0.01)；SD組閤併丁螺環酮治療後血清催乳素水平[(20.38±11.91)ng/ml]高于正常對照組[(14.2±12.15)ng/ml],差異有顯著性(P=0.008),但與SD組閤併用藥前[(18.15±9.84) ng/ml]相比差異無統計學意義(P=1.0).閤併丁螺環酮治療前患者ASEX總分與氟西汀(r=0.504,P=0.002)和帕囉西汀(r=0.377,P=0.013)劑量顯著相關.在正常組、NSD組以及SD組閤併丁螺環酮治療前後均未髮現ASEX總分與血催乳素水平顯著相關.結論 丁螺環酮輔助治療可能有助于緩解SSRI類抗抑鬱劑所緻的性功能障礙.
목적 탐토정라배동대사용5-HT재섭취억제제(SSRI)유지치료적완해기녀성억욱증환자성공능이급혈청최유소수평적영향.방법 사선120례이단일SSRI류항억욱제치료지소6월、구유고정배우、한밀이돈억욱량표17항판본(HMAD-17)평분소우7분적강복기억욱증녀성환자,이아리상나성경험량표(ASEX)판정성공능장애(SD)자40례,병여정라배동15～30 mg/d치료4주,필배사회인구학상부적정상대조조、비SD환자조(NSD)각40례,비교대조조、NSD조화정라배동치료전후SD조성공능화혈장최유색수평,병분석SD가능적림상상관인소.결과 120례강복기억욱증환자SD총체발생솔위33.3％,정라배동치료후성공능호전솔위60％.SD조합병정라배동치료후ASEX총분、5개분인자분치저우합병용약전,차이유현저성(균P＜0.01)；SD조합병정라배동치료후혈청최유소수평[(20.38±11.91)ng/ml]고우정상대조조[(14.2±12.15)ng/ml],차이유현저성(P=0.008),단여SD조합병용약전[(18.15±9.84) ng/ml]상비차이무통계학의의(P=1.0).합병정라배동치료전환자ASEX총분여불서정(r=0.504,P=0.002)화파라서정(r=0.377,P=0.013)제량현저상관.재정상조、NSD조이급SD조합병정라배동치료전후균미발현ASEX총분여혈최유소수평현저상관.결론 정라배동보조치료가능유조우완해SSRI류항억욱제소치적성공능장애.
Objective To determine the influence of buspirone on sexual function and plasma prolactin in rehabilitative female major depressive patients.Methods The female major depressive patients,who had a total HAMD-17 less than 7,were living with a sexual partner and receiving SSRI antidepressant monotherapy for at least six months were recruited.Sexual dysfunction (SD) was assessed using the Arizona Sexual Experience Scale (ASEX).The patients with SD were treated with buspirone 15 ～ 30 mg by 4 weeks.Sexua function and blood samples were compared among the control,non-SD patients,and the SD patients before or after treating with buspirone.The clinical risk factor of SD was also investigated with correlation analysis.Results The general incidence of SD in rehabilitative female major depressive patients was 33.3％.The improvement rate of SD was 60％ after the treatment of buspirone.The ASEX score and it 5 items were significantly decreased in the depressive patients after the treatment of buspirone (P ＜ 0.01 ).Prolactin in subjects treated with buspirone ( ( 20.38 ± 11.91 )ng/ml) was significantly higher than control ( ( 14.2 ± 12.15 ) ng/ml),but not higher than the period prior to treatment with buspirone ( ( 18.15 ±9.84) ng/ml).The ASEX score was significantly correlated the dose of fluoxetine( r=0.504,P=0.002) and paroxetine ( r=0.377,P=0.013).There was no significantly correlation between ASEX score and prolactin in the control,non-SD patients,and the patients before or after treating with buspirone.Conclusion Buspirone can release sexual dysfunction induced by SSRI antideptressant in the depressive patients.
